Tiziana Life Sciences Ltd
TLSA1.790USD
-0.010-0.56%
Market hours （ET）Quotes delayed by 15 min
212.69MMarket Cap
--P/E TTM
More Details of Tiziana Life Sciences Ltd Company
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
Tiziana Life Sciences Ltd Info
Ticker SymbolTLSA
Company nameTiziana Life Sciences Ltd
IPO dateNov 20, 2018
CEOMr. Ivor Elrifi
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 20
Address3rd Floor, 11-12 St. James's Square
CityLONDON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeSW1Y 4LB
Phone442074952379
Websitehttps://www.tizianalifesciences.com/
Ticker SymbolTLSA
IPO dateNov 20, 2018
CEOMr. Ivor Elrifi
Company Executives of Tiziana Life Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 30
Updated: Thu, Oct 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.01%
Dauntless Investment Group, LLC
2.88%
Citadel Advisors LLC
0.17%
Other
50.84%
Shareholders
Shareholders
Proportion
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.01%
Dauntless Investment Group, LLC
2.88%
Citadel Advisors LLC
0.17%
Other
50.84%
Shareholder Types
Shareholders
Proportion
Individual Investor
46.12%
Investment Advisor
3.36%
Investment Advisor/Hedge Fund
0.25%
Hedge Fund
0.18%
Research Firm
0.10%
Other
49.98%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
67
4.64M
3.91%
+430.59K
2025Q2
68
51.10M
45.84%
+9.72M
2025Q1
69
45.10M
40.46%
+3.34M
2024Q4
64
40.33M
36.45%
-5.07M
2024Q3
58
41.30M
37.43%
-3.04M
2024Q2
51
40.27M
36.45%
-4.04M
2024Q1
48
40.16M
36.35%
-4.27M
2023Q4
52
45.25M
44.24%
+1.19M
2023Q3
58
45.24M
44.24%
+1.10M
2023Q2
54
45.32M
44.32%
+1.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cerrone (Gabriele M)
42.04M
35.38%
+2.70M
+6.85%
Mar 31, 2025
Chernett (Jorey)
5.95M
5.01%
+5.95M
--
Jun 11, 2025
Dauntless Investment Group, LLC
3.42M
2.88%
+1.68M
+96.52%
Jun 30, 2025
Citadel Advisors LLC
198.99K
0.17%
+198.99K
--
Jun 30, 2025
HSBC Global Asset Management (UK) Limited
105.36K
0.09%
--
--
Jun 30, 2025
Zhang Financial LLC
89.76K
0.08%
-6.50K
-6.75%
Jun 30, 2025
Susquehanna International Group, LLP
86.08K
0.07%
+28.75K
+50.16%
Jun 30, 2025
HRT Financial LP
84.11K
0.07%
+13.74K
+19.53%
Jun 30, 2025
Kovitz Investment Group Partners, LLC
79.36K
0.07%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
Date
Type
Ratio
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
